» Articles » PMID: 21159250

[meta-analysis of Serum Tumor Markers in Lung Cancer]

Overview
Date 2010 Dec 17
PMID 21159250
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Objective: the detection of serum tumor markers is of great value for early diagnosis of lung cancer. The aim of this study is to summarize the clinic significance characteristics of serum markers contributing to the detection of lung cancer.

Methods: references about serum markers of lung cancer were estimated using meta-analysis method. 712 references which included more than 20 cases, 20 controls, the serum markers of 52 832 patients with malignancies and 32 037 patients as controls were evaluated.

Results: overall the detection of 13 markers play a significant part in lung cancer diagnosis. The sensitivity of CEA, CA125, CYFRA21-1, TPA, SCCAg, DKK1, NSE, ProGRP in the patients' serum with lung cancer were 47.50%, 50.11%, 57.00%, 50.93%, 49.00%, 69.50%, 39.73%, 51.48% and the specificity were 92.34%, 80.19%, 90.16%, 88.41%, 91.07%, 92.20%, 89.11%, 94.89%. In the combined analysis of tumor markers: the sensitivity, specificity of NSE+ProGRP were 88.90% and 72.82% in diagnosis of small cell lung cancer, respectively. In diagnosis of squamous corcinoma, the sensitivity and specificity of TSGF+SCCAg+CYFRA21-1 were 95.30% and 74.20%. The the sensitivity and specificity of CA153+Ferrtin+CEA were 91.90% and 44.00% in diagnosis of lung cancer.

Conclusions: although the assay of tumor markers in serum is useful for diagnosis of early lung cancer, the sensitivity and specificity are low. Combined detection of these tumor markers could increase sensitivity and specificity.

Citing Articles

Enumeration and Molecular Characterization of Circulating Tumor Cell Using an Epithelial Cell Adhesion Molecule/Vimentin/Epidermal Growth Factor Receptor Joint Capture System in Lung Cancer.

Jiang W, Wu J, Lin X, Chen Z, Lin L, Yang J Clin Med Insights Oncol. 2024; 18:11795549241231568.

PMID: 38525298 PMC: 10960340. DOI: 10.1177/11795549241231568.


Identification of key candidate tumor biomarkers in non-small-cell lung cancer by analysis.

Chen W, Zhu S, Zhang Y, Xiao J, Tian D Oncol Lett. 2020; 19(1):1008-1016.

PMID: 31897214 PMC: 6924182. DOI: 10.3892/ol.2019.11169.


[Expression and Clinical Significance of MAGE-C2 in Lung Adenocarcinoma].

Guo K, Lu M, Xu P, Li H Zhongguo Fei Ai Za Zhi. 2016; 19(2):88-92.

PMID: 26903162 PMC: 6015139. DOI: 10.3779/j.issn.1009-3419.2016.02.09.


Expression and significance of squalene epoxidase in squamous lung cancerous tissues and pericarcinoma tissues.

Zhang H, Li H, Yu Z, Yu X, Guo K Thorac Cancer. 2016; 5(4):275-80.

PMID: 26767013 PMC: 4704350. DOI: 10.1111/1759-7714.12087.


Diagnostic value of circulating microRNAs for lung cancer: a meta-analysis.

Shen Y, Wang T, Yang T, Hu Q, Wan C, Chen L Genet Test Mol Biomarkers. 2013; 17(5):359-66.

PMID: 23387316 PMC: 3634145. DOI: 10.1089/gtmb.2012.0370.


References
1.
Schneider J . Tumor markers in detection of lung cancer. Adv Clin Chem. 2006; 42:1-41. DOI: 10.1016/s0065-2423(06)42001-1. View

2.
Zaleska M, Szturmowicz M, Zych J, Roszkowska-Sliz B, Demkow U, Langfort R . [Elevated serum NSE level in locally advanced and metastatic NSCLC predispose to better response to chemotherapy but worse survival]. Pneumonol Alergol Pol. 2010; 78(1):14-20. View

3.
Racil H, Saad S, Cheikh Rouhou S, Chaouch N, Zarrouk M, Yaalaoui S . [The value of tumor markers in pulmonary tuberculosis]. Tunis Med. 2009; 87(5):330-3. View

4.
Holdenrieder S, von Pawel J, Dankelmann E, Duell T, Faderl B, Markus A . Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cell lung cancer. Clin Cancer Res. 2008; 14(23):7813-21. DOI: 10.1158/1078-0432.CCR-08-0678. View

5.
Weber D, Johnen G, Taeger D, Weber A, Gross I, Pesch B . Assessment of Confounding Factors Affecting the Tumor Markers SMRP, CA125, and CYFRA21-1 in Serum. Biomark Insights. 2010; 5:1-8. PMC: 2814766. DOI: 10.4137/bmi.s3927. View